RenovaCare, Inc. (OTCPK: RCAR)
Health Care · Biotechnology · US
$0.00
— today · 0.0% 1Y
RenovaCare, Inc. (OTCPK: RCAR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $87.00 and employs 1 people.
Over the last twelve months the share price has gained 0.0%, trading between 0.00 and 0.00.
Tweenvest scores RenovaCare, Inc. across four factors: quality 13/100. Its strongest factor is quality.
RCAR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $87.00
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.07
- Dividend yield
- —
- Beta (5Y)
- -91.41
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 87.35M
- Employees
- 1
- Next earnings
- —
About RenovaCare, Inc.
RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name RenovaCare, Inc.,to RenovaCare, Inc. in January 2014. RenovaCare, Inc. was incorporated in 1983 and is based in Scottsdale, Arizona.
- ISIN
- US75988J1060
- Founded
- 1983
- Listed since
- May 30, 1996
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.61 | -1.57% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.27 | +0.01% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.80 | +0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $550.52 | -0.42% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $823.79 | -1.17% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $146.35 | -7.86% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.